SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QDEL - Quidel more quick diagnosis
QDEL 26.60+9.2%Nov 24 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dennis C who wrote (465)3/3/1997 3:12:00 PM
From: Robert Busse   of 1693
 
Dennis,

Thanks for the press release on CMTR's test. Qdel has already "been there, done that", so to speak.
According to H. pylori foundation home page, Qdel's Quickvue hp test has been shown by "clinical studies
" to have a sensitivity of 98% and "overall accuracy of 95% vs.culture/histology recorded by E.I.A."
Qdel's tests was approved in early Feb, 1996, more than a year ago. They still have something neither Merck or CMTR
can claim (a CLIA waiver) which automatically give QDEL/P+G a market which is approx. 25,000 locations larger than CMTR/Merck. I still think Qdel is leading the way in this area.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News